AI driven allergy Leveraging Ukko's AI and protein engineering focus to position as a partner for pharmaceutical and biotech firms seeking safer, targeted immunotherapies for allergies, enabling co-development or licensing conversations.

Allergy desensitization Target opportunities with healthcare providers and payers interested in precision prevention of life-threatening peanut reactions, exploring collaborations on safer desensitization platforms or adjunct therapies.

Large funding momentum Capitalize on recent Series B funding led by Leaps by Bayer to open doors with strategic investors, pharma partners, and grant programs; propose joint development or sponsored research initiatives.

Scale and capability With a mid-size team and $93M funding, pursue services or technology licensing for AI-driven protein design, analytics tooling, and platform capabilities that can be commercialized to accelerate allergy research pipelines.

Industry alignment Position Ukko as a bridge between biotech tooling and clinical applications by offering integratable research platforms, data collaboration, and regulatory-ready solutions to accelerate immunotherapy development for allergy and immune-mediated conditions.